| Program | Target | Format | Discovery | Preclinical | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|---|---|
| POB-1032 | MC4R | Peptide | |||||
| POB-016 | GLP-1/GIP | Biologic | |||||
| POB-027 | FGF21 | Biologic | |||||
| POB-1374 | FGF21; GLP-1 | Fusion Protein | |||||
| POB-062 | β2AR | To be disclosed | |||||
| POB-048 | ACVR2 | Biologic | |||||
| POB-0526 | GOAT | Small Molecule | |||||
| POB-0119 | GDF15 | Biologic | |||||
| POB-022 | To be disclosed | To be disclosed | |||||
| POB-079 | To be disclosed | To be disclosed | |||||
Explore New Frontiers
We fully recognize that overcoming obesity—a global challenge—requires pooling worldwide expertise. To this end, we are actively expanding innovative anti-obesity therapies and sincerely invite scientists from around the world to join us in collaboration. We look forward to working with you on cutting-edge obesity treatment research projects. Through resource sharing and knowledge exchange, we aim to accelerate the development of novel therapies and deliver superior treatment options.
Complement System
Complement system is a natural defence line of immune system against invasive pathogens through direct cytolysis or stimulation of phagocytosis, contributing to the inflammation and homeostasis.
ComPLET™ Hemolysis Assay Solutions
Creative Biolabs developed a comprehensive ComPLET™ Hemolysis Assay platform to support our clients' complement therapy research. We offer all kinds of hemolysis assays to best suit your program requirements.
Pioneering a New Chapter in Obesity Treatment: Collaboration Opportunities
Protheragen is at the forefront of innovation in obesity therapy, targeting key biomarkers, and has established a scientifically rigorous pipeline for the development of anti-obesity drugs. We are committed to addressing the future challenges of obesity treatment and invite biotechnology innovators, pharmaceutical industry leaders, and digital health pioneers to explore potential collaboration opportunities and research obesity treatment together. If you are interested, please do not hesitate to contact us to learn more about our cutting-edge research in obesity treatment.